NEW YORK, Sept. 14, 2021 /PRNewswire/ — ObvioHealth, a global virtual research organization (VRO), announces key hires to round out its executive leadership team. Seeded four years ago by SGI, ObvioHealth has entered into a phase of more rapid growth and a need for an upsized team to address market demand.
Since taking the helm at ObvioHealth, CEO and Co-founder Ivan Jarry, has grown the company 13-fold. Ivan leveraged advances in digital technology to tackle the inefficiencies in clinical research, designing one of the first patient-centric apps for decentralized clinical trials. Since then, he has put agile teams and processes in place to quickly scale the business.
Recent additions to the C-Suite include:
ObvioHealth has added 45 employees to its staff since the beginning of the year and the company has plans for 20 additional hires in the US and Asia by the end of 2021. The Singapore office will become the company’s regional technology hub, collaborating with the US platform team to drive expansion of decentralized trials to APAC.
These developments come at an exciting time for ObvioHealth, as the company recently announced the first close of its series B financing round. The digital tech start-up has also signed strategic partnership agreements with Asia-Pacific biotech-specialist CRO Novotech, Europe-based healthcare software company Dedalus, and IQVIA Consumer Health, expanding ObvioHealth’s global reach and capabilities.
“We started this company with a handful of employees and a vision to make clinical research more efficient,” said Ivan Jarry, CEO of ObvioHealth. “Four years later, we are pleased with our growth trajectory as we continue to pioneer new ways to collect data through virtual research.”
About ObvioHealth
ObvioHealth is an end-to-end Virtual Research Organization (VRO) that delivers better data to sponsors and an easier clinical trial experience for participants. The company developed and launched one of the first DCT apps, downloadable on smartphones enabling people to participate in clinical trials from the comfort of their homes. In the 4 years since launch, the company has been awarded 40+ studies from 28 blue chip clients, implemented in 28 countries, in 16 different therapeutic areas. For more information, visit https://www.obviohealth.com.
About SPRIM Global Investments
SPRIM Global Investments (SGI) is a healthcare and life science-focused investment company with offices in New York and Singapore with major focuses on healthcare IT and biotech across stages and therapeutic areas. Further information can be found at www.sprim.com.
SOURCE ObvioHealth
LOS ANGELES, Jan. 11, 2025 /PRNewswire/ -- Demonstrating a commitment to both innovation and compassion,…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced…
BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American:…
Craig Swandal, experienced medical device manufacturing executive, joins leadership teamALACHUA, Fla. and TAMPA, Fla., Jan.…
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…